prikaz prve stranice dokumenta Nintedanib treatment for bleomycin-induced lung injury - First report
  Preuzmi
PDF 1.89 MB
Znanstveni rad - Prikaz slučaja
Nintedanib treatment for bleomycin-induced lung injury - First report
Respiratory Medicine Case Reports, 46 (2023); 101921. https://doi.org/10.1016/j.rmcr.2023.101921
Rnjak, Dina; Batarilo Hađar, Martina; Pelicarić, Dubravka; Vukić, Tea; Janković Makek, Mateja; Samaržija, Miroslav; Hećimović, Ana

Citirajte ovaj rad

Rnjak, D., Batarilo Hađar, M., Pelicarić, D., Vukić, T., Janković Makek, M., Samaržija, M. i Hećimović, A. (2023). Nintedanib treatment for bleomycin-induced lung injury - First report. Respiratory Medicine Case Reports, 46.. doi: 10.1016/j.rmcr.2023.101921

Rnjak, Dina, et al. "Nintedanib treatment for bleomycin-induced lung injury - First report." Respiratory Medicine Case Reports, vol. 46, 2023. https://doi.org/10.1016/j.rmcr.2023.101921

Rnjak, Dina, Martina Batarilo Hađar, Dubravka Pelicarić, Tea Vukić, Mateja Janković Makek, Miroslav Samaržija i Ana Hećimović. "Nintedanib treatment for bleomycin-induced lung injury - First report." Respiratory Medicine Case Reports 46 (2023). https://doi.org/10.1016/j.rmcr.2023.101921

Rnjak, D., et al. (2023) 'Nintedanib treatment for bleomycin-induced lung injury - First report', Respiratory Medicine Case Reports, 46. doi: 10.1016/j.rmcr.2023.101921

Rnjak D, Batarilo Hađar M, Pelicarić D, Vukić T, Janković Makek M, Samaržija M, i sur.. Nintedanib treatment for bleomycin-induced lung injury - First report. Respiratory Medicine Case Reports [Internet]. 27.09.2023. [pristupljeno 18.07.2024.];46. doi: 10.1016/j.rmcr.2023.101921

D. Rnjak, et al., "Nintedanib treatment for bleomycin-induced lung injury - First report", Respiratory Medicine Case Reports, vol. 46, Rujan 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:407335. [Citirano: 18.07.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:407335
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Nintedanib treatment for bleomycin-induced lung injury - First report
AutorDina Rnjak
AutorMartina Batarilo Hađar
AutorDubravka Pelicarić
AutorTea Vukić
AutorMateja Janković Makek
AutorMiroslav Samaržija
AutorAna Hećimović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients. The optimal treatment for bleomycin lung toxicity has not been established and no clinical trials have been performed. Here we present first successful case report of nintedanib therapy in a patient with bleomycin-induced lung injury (BILI). The prevention, early diagnosis, and management of bleomycin pulmonary toxicities are essential, clinical trials are needed in this area.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaRespiratory Medicine Case Reports
Brojčani podacivol. 46, 101921
p-ISSN2213-0071
DOIhttps://doi.org/10.1016/j.rmcr.2023.101921
URN:NBNurn:nbn:hr:105:407335
Datum objave publikacije2023-09-27
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S2213007123001168
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2024-05-17 08:44:23